Masimo SEC Filings

Type
Report
Date
PREM14APREM14A-Formular3/18/2026
4Insidertransaktion3/16/2026
4Insidertransaktion3/16/2026
4Insidertransaktion3/13/2026
4Insidertransaktion3/10/2026
4Insidertransaktion3/10/2026
4Insidertransaktion3/10/2026
4Insidertransaktion3/10/2026
4Insidertransaktion3/10/2026
4Insidertransaktion3/10/2026
4Insidertransaktion3/10/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular3/6/2026
4Insidertransaktion3/3/2026
DFAN14ADFAN14A-Formular2/27/2026
10-KJahresbericht2/27/2026
4Insidertransaktion2/26/2026
SCHEDULE 13D/ASCHEDULE 13D/A-Formular2/17/2026
DFAN14ADFAN14A-Formular2/17/2026
DEFA14ADEFA14A-Formular2/17/2026
DEFA14ADEFA14A-Formular2/17/2026
DEFA14ADEFA14A-Formular2/17/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/17/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/13/2026
4Insidertransaktion2/13/2026
4Insidertransaktion1/30/2026
144144-Formular1/28/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular1/21/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/12/2026
144144-Formular12/11/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/3/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/1/2025
144144-Formular11/28/2025
4Insidertransaktion11/17/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/12/2025
10-QQuartalsbericht11/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/29/2025
144144-Formular9/29/2025
144144-Formular9/26/2025
4Insidertransaktion9/25/2025
144144-Formular9/23/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/23/2025
4Insidertransaktion9/3/2025
33-Formular9/3/2025
4Insidertransaktion8/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/19/2025
4Insidertransaktion8/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular8/12/2025
4Insidertransaktion8/12/2025
33-Formular8/11/2025
4Insidertransaktion8/11/2025
33-Formular8/11/2025
33-Formular8/11/2025
10-QQuartalsbericht8/5/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/5/2025
4Insidertransaktion7/3/2025
11-K11-K-Formular6/26/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/12/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/27/2025
SDSD-Formular5/27/2025
4Insidertransaktion5/14/2025
144144-Formular5/13/2025
144144-Formular5/12/2025
144144-Formular5/12/2025
8-K/A8-K/A-Formular5/7/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/6/2025
10-QQuartalsbericht5/6/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/6/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/6/2025
4Insidertransaktion5/2/2025
4Insidertransaktion5/2/2025
4Insidertransaktion5/2/2025
4Insidertransaktion5/2/2025
4Insidertransaktion5/1/2025
4Insidertransaktion5/1/2025
4Insidertransaktion5/1/2025
4Insidertransaktion5/1/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/30/2025
144144-Formular4/24/2025
4Insidertransaktion4/23/2025
33-Formular4/23/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4/22/2025
DEF 14ADEF 14A-Formular3/26/2025
4Insidertransaktion3/14/2025
4Insidertransaktion3/14/2025
144144-Formular3/14/2025
4Insidertransaktion3/13/2025
4Insidertransaktion3/13/2025
4Insidertransaktion3/12/2025
144144-Formular3/10/2025
4Insidertransaktion3/4/2025
4Insidertransaktion3/4/2025
4Insidertransaktion3/4/2025
SCHEDULE 13GSCHEDULE 13G-Formular3/4/2025
144144-Formular3/3/2025
144144-Formular3/3/2025
S-3ASRS-3ASR-Formular2/26/2025
POSASRPOSASR-Formular2/25/2025
10-KJahresbericht2/25/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/25/2025

Masimo Documents 2026

This page contains all official documents and SEC filings for Masimo stock (MASI, ISIN: US5747951003). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Masimo's regulatory filings.

Masimo Stock analysis

Masimo Masimo Corporation is an American medical technology company based in Irvine, California. The company was founded in 1989 by Professor Joe Kiani, who is still the chairman and CEO of the company today. With innovative products and advanced technology, Masimo aims to optimize medical diagnostic and treatment procedures to improve patient care. The business model of Masimo Corp focuses on developing and marketing products and solutions for patient monitoring and treatment in hospitals, intensive care facilities, and outpatient clinics. The company relies on high levels of innovation and collaboration with physicians, scientists, and other experts. The goal is to improve existing medical procedures, explore new applications for the technology, and optimize patient care. Masimo Corp's products are divided into different divisions that focus on various aspects of medical care. One example is the "Patient Monitoring" division, which offers various monitoring systems for vital signs such as respiration, pulse, and oxygen saturation. This includes products like the Rad-67 pulse oximeter or the Root patient monitor, which continuously monitor patients during treatment to enhance safety and effectiveness. Another division is "Anesthesia and Sedation," which focuses on solutions for anesthesiologists and intensive care specialists. Masimo Corp offers products such as the SedLine brain monitor or the EMMA main gas monitor, which enable physicians to control anesthesia depth more precisely and reduce the risk of complications. In addition to patient monitoring systems, Masimo Corp also provides solutions for neonatal care. The "Neonatal Care" division includes products like the Masimo Radical-7 pulse oximeter for monitoring premature infants or the Pronto-7 pulse oximeter for fast and accurate monitoring of newborns in the delivery room. Furthermore, Masimo Corp has developed products for monitoring surgical patients. The "Surgical and Minimally Invasive Monitoring" division, for example, offers the MOC-9 monitoring system for precise monitoring of hemodynamics during surgery. A unique product of Masimo Corp is also the Masimo SET sensor, which provides more accurate and reliable measurement of blood oxygen saturation than traditional pulse oximeter sensors. The company has filed over 100 patents worldwide for this technology and has been recognized with numerous awards and accolades. In summary, Masimo Corp is an innovative company specializing in improving medical care through the development and marketing of products for patient monitoring and treatment. With its state-of-the-art technologies and collaboration with experts in medical research, Masimo Corp sets standards for patient safety and treatment effectiveness.